EDMONTON, May 8 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that the Company will web cast its Annual General and Special Meeting in Montreal on Tuesday, May 9, 2006 at 10:00 a.m. ET. The web cast will include corporate and scientific updates. The web cast will be chaired by Dr. Robert Foster, Executive Chairman; with Dr. Randall Yatscoff, President and CEO presenting the corporate and scientific update.
Interested parties can access the live web cast by logging on to the Company's Web site at www.isotechnika.com. A recording of the web cast will be archived for a 180 day period through the web cast archives at www.newswire.ca and on the Company's Web site.
About Isotechnika Inc.
----------------------
Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis. In addition, ISA247 has successfully completed a Phase IIa trial for kidney transplantation. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which is in Phase I.
Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.
Forward-Looking Statements
--------------------------
This press release may contain forward-looking statements. Forward- looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward- looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
Isotechnika Inc.CONTACT: Stephanie Gillis-Paulgaard, Director, Corporate Communications,Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105, E-mail:sgillis-paulgaard@isotechnika.com
